---
title: "HarborSite: Research-stage platform for inserting therapeutic genes into safe genomic sites with engineered recombinases"
url: https://emrr.uz/harborsite
language: en
updated: 2026-11-19T20:06:51Z
source: emrr (https://emrr.uz)
---

# HarborSite

Research-stage platform for inserting therapeutic genes into safe genomic sites with engineered recombinases

[harborsite.com](https://www.harborsite.com/)

- **Industry**: Biotech
- **Based in**: United States

## Verified revenue: not connected yet

Is HarborSite yours? Claim this page and connect Stripe, the App Store or Google Play: your MRR and growth show here, read straight from the source.

[Claim it if it’s yours](https://panel.emrr.uz/reserve/harborsite)

## About

HarborSite is a Harvard/Wyss Institute spinoff developing engineered recombinase enzymes to insert full-length therapeutic genes into safe sites in the genome, aiming at one-time treatments for genetic and age-related diseases. It is at research stage, with an initial focus on liver and blood cells. It is based in Boston, US, and is backed by Armenia-based SmartGate VC.

## Team

- **Erik Aznauryan**, Co-founder and CEO (Founder)
- **George Church**, Co-founder and Scientific Advisory Board Chair (Founder)
- **Tina Lebar**, Co-founder and Scientific Advisory Board Member (Founder)

## Audience

Followers on social networks

- [X @harborsitetx](https://x.com/harborsitetx)
- [LinkedIn harborsite](https://www.linkedin.com/company/harborsite/)

Profile data from Stanbase.

Updated 19 November 2026

[This page in Markdown](https://emrr.uz/harborsite.md)

[Get your verified page](https://emrr.uz/): Connect Stripe, the App Store or Google Play in two minutes and get a page like this one. emrr reads every figure itself, so investors don’t have to take your word for it. Free while MRR is under $1,000.
